Bard pays $200mm up front for hemostasis management company Medafor
Executive Summary
CR Bard Inc. has paid $200mm up front in cash ($7.08 per share) to acquire Medafor Inc., a private maker of absorbable hemostatic agents. Medafor is also entitled to up to $80mm in earn-outs (equating to $2.82 per share) if revenue goals are met through June 30, 2015.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice